TABLE 4.
Percent susceptible for imipenem-relebactam and comparator agents by resistance genotype
| Agenta | Total no. (% of 203) | No. KPC (%) (n = 35) | P valueb | No. NDM (%) (n = 16) | P valueb | No. OXA-48 (%) (n = 9) | P valueb | No. CTX-M (%) (n = 84) | P valueb | No. CMY-2 (%) (n = 58) | P valueb |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I-R | 180 (89) | 35 (100) | * | 1 (6) | *** | 6 (67) | * | 72 (86) | 50 (86) | ||
| IPM | 90 (44) | 0 (0) | *** | 0 (0) | *** | 1 (11) | * | 51 (60) | *** | 25 (43) | |
| MEM | 153 (75) | 19 (54) | ** | 1 (6) | *** | 7 (78) | 64 (76) | 49 (84) | |||
| ETP | 7 (3) | 0 (0) | 1 (6) | 0 (0) | 3 (4) | 4 (7) | |||||
| GEN | 132 (65) | 17 (49) | * | 4 (25) | *** | 6 (67) | 45 (54) | ** | 47 (81) | ** | |
| TZP | 56 (28) | 2 (6) | ** | 1 (6) | * | 0 (0) | 31 (37) | * | 13 (22) | ||
| AMK | 163 (80) | 27 (77) | 10 (63) | 7 (78) | 59 (70) | ** | 56 (97) | *** | |||
| LVX | 40 (20) | 10 (29) | 0 (0)* | 1 (11) | 1 (1.2) | *** | 23 (40) | *** | |||
| TGC | 200 (99) | 35 (100) | 15 (94) | 9 (100) | 84 (100) | 57 (98) | |||||
| CAZ | 19 (9) | 1 (3) | 1 (6) | 2 (22) | 2 (2) | ** | 0 (0) | ** | |||
| CL | 201 (99) | 33 (94) | ** | 16 (100) | 9 (100) | 84 (100) | 58 (100) | ||||
| MIN | 141 (69) | 28 (80) | 6 (37) | ** | 5 (56) | 51 (60) | * | 38 (65) |
a
AMK, amikacin; CAZ, ceftazidime; CL, colistin; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; I-R, imipenem-relebactam; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TGC, tigecycline; TZP, piperacillin-tazobactam.
b
P value (by chi-square test) for indicated group versus all others. *, P < 0.05; **, P < 0.01; ***, P ≤ 0.001.